Renalytix Dividends - RENX | ADVFN

Gold vs US Dollar

LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.

Home
Investing
Stocks
UK
LSE
Renalytix Plc (RENX)
Renalytix Plc (RENX) Dividends

Share Name	Share Symbol	Market	Stock Type
Renalytix Plc	RENX	London	Ordinary Share

	Price Change	Price Change %	Share Price	Last Trade
	0.00	0.0%	87.50	08:00:00

Open Price	Low Price	High Price	Close Price	Previous Close
87.50	87.50	87.50	87.50	87.50

more quote information »

Industry Sector
PHARMACEUTICALS & BIOTECHNOLOGY

Renalytix RENX Dividends History

No dividends issued between 03 Jun 2013 and 03 Jun 2023

Top Dividend Posts

Top Posts
Posted at 30/5/2023 11:44 by wantage WanMuch appreciate your sleuthing and sharing Renx info. Keep up the good work. Read Full Thread Follow Reply
Posted at 21/4/2023 05:35 by mrmarmalade Hi Wan...I really appreciate the work you put in here keeping us informed good or bad. I was wondering if there was a Telegram channel for RENX? BW MM Read Full Thread Follow Reply
Posted at 14/2/2023 13:46 by apatel21 Share price strength here is encouraging given the price placing was done at.Normally see price head south towards placing price.I think Renx has been leaky in the past - is it therefore an indicator of some good news to come ? Read Full Thread Follow Reply
Posted at 08/2/2023 12:07 by red171 Idomeneo Perhaps it was hopium bs chosing to raise just $20m. It seems nothing like enough based on bf $31 cash from Q1, Q2 revenue $1 less burn of $(12) [on admin (8) & R&D (4)] = loss $(11) in Q2. So $20 cf into this quarter +$20 raised & loss of $(11)= net inflow $9 unless revenue changes so starting Q4 with $29 buring at $(11) p Qtr - or a run way just over 6 mths. It does seem like they pulled out their best news to support this raise & they are counting on another one should there be a significant announcement (like on FDA. Otherwise, wouldn't Mills & other IIs would not benefit more by taking RENX off the market to fund the obvious shortfall in runway? Perhaps they believe a "milestone heavy short term" as McCulloch expected 30 Nov is the most likely outcome rather than it looks from outside as just continuation of "the apparent industrial scale of lying that the board appear to have indulged" as you put it a while ago. Read Full Thread Follow Reply
Posted at 30/1/2023 06:34 by wan I am sure most readers will have already seen the following article, where Nephrology Associates of Syracuse, P.C. confirm that they now use KidneyIntelX. Readers will also note that “KidneyIntelX uses a set of newer, novel blood and urine tests to give better predictive values of whether someone is at high risk for kidney failure progression that will ultimately lead to a need for dialysis.” Note the discrete mention of a novel urine test - hTTps://www.centralnewyorkmdnews.com/articles/nephrology-associates-of-syracuse-p-c-give-patients-a-comprehensive-united-approach-to-kidney-care/ If that use/reference of novel is correct, could that novel urine test be from the partnership with the University of Michigan- Partnership agreement with the University of Michigan NEW YORK, June 30, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), today announced a partnership with the University of Michigan ("UM") to extend the application of the KidneyIntelX:tm: platform to an expanded population of patients with established Chronic Kidney Disease (CKD) or at risk of developing CKD. RenalytixAI also announces a data sharing agreement with a top ten global pharmaceutical company. RenalytixAI has entered into a partnership with the University of Michigan ("UM") under which RenalytixAI will be given access to the Clinical Phenotyping Resource and Biobank Core ("C-PROBE") of the UM George M. O'Brien Kidney Translational Core Center comprising of over 800 patients with a broad etiology of CKD with up to 10 years of follow up. Additionally, through this partnership, RenalytixAI has obtained an exclusive option under which it can license certain intellectual property surrounding the biomarker urinary Epithelial Growth Factor ("uEGF"). Prof. Matthias Kretzler and his team at UM have shown uEGF to be highly predictive of incident and progressive CKD1. hTTps://investors.renalytixai.com/news-releases/news-release-details/renalytixai-announces-partnership-university-michigan-extend Read Full Thread Follow Reply
Posted at 28/1/2023 08:58 by faz I do mot say they are simple mathematical formulae and sorcerors are not creators of modelling tools. Whatever, i hope renx do save lives.and thrive but they need to get thru this year successfully or i doubt they have a future Read Full Thread Follow Reply
Posted at 26/1/2023 18:51 by faz Wan, you'll see I wrote AI remains a conundrum, and if it was so blindingly obvious that the algorithms created by RENX are so far superior to relevant human endeavour then approval would have been granted a long time ago. A mathamatical formula is a subset of an algorithm, and if you;ve ever worked with excel professionals you'd never have dismissed their capability so blindly. 'Exclusive validated novel biomarkers' - get behind those words. It starts with mathamatical formulae, then into algorithsm that in theory generate outcomes that are then subject to differents sets of algorithmic calculations. People can do that too; hence the issue. it's a do or die year for RENX. Read Full Thread Follow Reply
Posted at 26/1/2023 09:44 by wan One assumes that the pandemic set things back somewhat, but it's also worth recalling the original agreement between Renalytix and the University of Michigan, which adds weight to my pharma comments given the reference to a top 10 pharma - NEW YORK, June 30, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced a partnership with the University of Michigan ("UM") to extend the application of the KidneyIntelX™ platform to an expanded population of patients with established Chronic Kidney Disease (CKD) or at risk of developing CKD. RenalytixAI also announces a data sharing agreement with a top ten global pharmaceutical company. Partnership agreement with the University of Michigan RenalytixAI has entered into a partnership with the University of Michigan ("UM") under which RenalytixAI will be given access to the Clinical Phenotyping Resource and Biobank Core ("C-PROBE") of the UM George M. O'Brien Kidney Translational Core Center comprising of over 800 patients with a broad etiology of CKD with up to 10 years of follow up. Additionally, through this partnership, RenalytixAI has obtained an exclusive option under which it can license certain intellectual property surrounding the biomarker urinary Epithelial Growth Factor ("uEGF"). Prof. Matthias Kretzler and his team at UM have shown uEGF to be highly predictive of incident and progressive CKD1. The first phase of the partnership with UM, expected to be completed in 2020, will study the potential role of uEGF in further enhancing the prognostic performance of the KidneyIntelX platform in identifying patients at highest risk of fast-progressing Diabetic Kidney Disease ("DKD") and kidney failure. Significantly, through this partnership, RenalytixAI plans to advance the development and validation of the KidneyIntelX platform for expanded use in a broad CKD population. The C-PROBE biobank provides RenalytixAI with access to a large repository of longitudinally followed CKD patients with matched urine and plasma samples coupled with extensive medical records. The patient population in the CPROBE study includes a range of CKD subtypes including those related to Diabetes, Hypertension and Glomerular Disease which combined, account for over 75 percent2 of all cases worldwide. Data sharing agreement with a leading top ten global pharmaceutical company RenalytixAI also announces that it has entered into a data sharing agreement with a top ten global pharmaceutical company providing RenalytixAI with access to a deep data repository from completed clinical studies in DKD. RenalytixAI plans to analyze this data in combination with corresponding biomarker data to evaluate KidneyIntelX performance in predicting patients' responses to novel therapeutic agents indicated to slow or prevent kidney function decline. Data analysis will also include evaluation of KidneyIntelX over multiple time points within a six year follow-up period, potentially demonstrating the value of dynamic, repeated KidneyIntelX measurements. "The primary aim of our research has always been the translation of findings to clinical practice in order to improve patient care and kidney health," said Prof. Matthias Kretzler, Warner-Lambert/Parke-Davis Professor of Medicine, Nephrology/Internal Medicine, and Computational Medicine and Bioinformatics, University of Michigan Medical School. "The C-PROBE cohort was established with the express aim of enabling this translation to take place. We are very excited to partner with RenalytixAI in this endeavor and firmly believe that KidneyIntelX platform is an ideal vehicle to integrate the results of our work on uEGF with other biomarkers, bioinformatics and clinical research, with the goal of providing new, powerful solutions in managing CKD." "These partnerships are both significant developments for our technology development roadmap and strategic objectives for the company," said Fergus Fleming, Chief Technology Officer and Co-founder of RenalytixAI. "Access to these data sets and samples potentially demonstrates the value of the KidneyIntelX platform and our ability to collaborate with leaders in discovery, clinical care and novel therapeutic development for kidney disease. We expect that gaining access to this clinical trial data, biomarker technology and the C-PROBE cohort will be key milestones in the development of expanded indications for KidneyIntelX, potentially allowing us to offer solutions to a greater number of the approximately 37 million patients currently estimated to have CKD." KidneyIntelX is a first-in-class in vitro diagnostics platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs including validated blood-based biomarkers, a patient's genetics and extensive personalized patient data from EHR systems to generate a unique patient risk score. The current intended use for the test targets patients with CKD and type 2 diabetes which accounts for 20-30 percent of the estimated 37M US patients with CKD3. hTTps://investors.renalytixai.com/news-releases/news-release-details/renalytixai-announces-partnership-university-michigan-extend Read Full Thread Follow Reply
Posted at 26/1/2023 08:12 by faz I thnk its more likkely RENX is clamouring for cash and if this chucks in anything then all to the good. FDA blessing is a must. I now hold a trading position at around 100p so well up, but this year is do or die for the company. AI remains a conundrum - just a dressed-up excel spreadsheet or something more than the best statisticians do routinely for the GSK, AZ etc? Read Full Thread Follow Reply
Posted at 18/9/2022 11:16 by mikemine1 Despite your last points, I didn't immediately see any relevance to RENX. It was more for the Trellus BB but you had already posted there. Reading it again, I see why you posted it here. The importance of early diagnosis, or at least warning signs, shouldn't need re-stating but it does it seems. Early detection of problems by tests are often critical and are what clinicians are always desperately seeking, KidneyintelX just one of the new breed now joined by CDPATH. Older tests that come in at a more established stage of a disease will quickly become obsolete and discarded, leaving the companies that own them having a bare cupboard and exposed. They will be forced in to collaboration or ownership of the likes of RENX and Takeda just to stay in the game. The point about Big Pharma's paying for the test is well spotted. This could be used whilst waiting for the insurance companies to agree to pay for the tests. Fortunately RENX have gone beyond this and have multiple agreements with insurance companies and institutions to pay for the tests which are now being increasingly used by clinicians. RENX are focusing on 3 key geographical areas where the insurance coverage is the most concentrated and it'll be interesting to hear of their progress there. The lack of FDA approval is no hindrance to RENX's ability sell to, promote within or infiltrate the medical establishment. A point vehemently made by McCullough in the last video. I know you know all this but I thought I'd put it down here to clarify my thoughts and perhaps remind others of the enormity of what RENX has in the field of Renal medicine. They need another 6-9 months to really established themselves as what they should be IMHO but, in the meantime, their quarterly updates should show increasing revenue and penetration of the market. The market will not be able to ignore that.It's more or less what McCullough said. Read Full Thread Follow Reply

Your Recent History

LSE

RENX

Renalytix

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea

V: D: 20230603 11:25:32